The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.
Access to MS Care in Underserved and Diverse Populations: Marisa McGinley, DOFebruary 26th 2023
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke at the 2023 ACTRIMS Forum about disparities in care access for patients with MS. [WATCH TIME: 5 minutes]
Long-term Ozanimod Treatment in Relapsing Multiple Sclerosis Associated With Stable or Improved Disease Activity and SafetyFebruary 26th 2023
An ad hoc analysis of patients from a pair of phase 3 clinical trials and an open-label extension suggest that more than 5 years of treatment with ozanimod (Zeposia; BMS) was safe, without differences in age groups.
Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple SclerosisFebruary 25th 2023
Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical disease activity in both unadjusted and adjusted analyses.
BTK Inhibitor Evobrutinib Displays Superior Efficacy Compared With Anti-CD20 Treatment for MSFebruary 25th 2023
A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized neuroinflammation in multiple sclerosis compared with anti-CD20 treatment.
Cognition Stabilized in Highly Active Relapsing MS on CladribineFebruary 24th 2023
Between pre-treatment naïve patients and those previously on disease-modifying therapies, treatment with cladribine resulted in stable scores on Symbols Digit Modalities Test and other cognitive assessments.
Gauging MS Disease Activity Through Octave’s MSDA Test: Taylor Gonyou, DOFebruary 24th 2023
The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]
Glatiramer Acetate Depot Injection Shows T1 and T2 Lesion Reduction in Relapsing MSFebruary 24th 2023
Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.
Disability Progression Risk Lowered in Diverse Patients With Relapsing MS on OcrelizumabFebruary 23rd 2023
Non-Hispanic Black and Hispanic or Latino individuals on ocrelizumab did not demonstrate significantly greater risk on 24-week confirmed disability progression relative to non-Hispanic Whites.
Emerging Concepts in Multiple Sclerosis and Reversing Neurodegeneration: Daniel Ontaneda, MDFebruary 23rd 2023
The program committee vice-chair of ACTRIMS discussed the continued efforts to understand inflammation and neurodegeneration of multiple sclerosis. [WATCH TIME: 3 minutes]
Inside Look at Themes, Sessions at ACTRIMS 2023 Forum: Daniel Ontaneda, MDFebruary 22nd 2023
The program committee vice-chair of ACTRIMS provided perspective on the upcoming forum, including the notable sessions, themes, and presentations the clinical community should be aware of. [WATCH TIME: 7 minutes]
ACTRIMS 2023: What to Expect From the Annual ForumFebruary 20th 2023
Daniel Ontaneda, MD, program committee vice-chair of ACTRIMS, provided insight on the notable sessions and themes clinicians should pay attention to at this year’s forum, which takes place February 23-25, in San Diego, California.
Where Tolebrutinib and Other BTK Inhibitors Fit in the MS Treatment Landscape: Jiwon Oh, MD, PhDMarch 15th 2022
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]
Overview of Tolebrutinib’s Positive 18-Month Data in Relapsing MS: Jiwon Oh, MD, PhDMarch 10th 2022
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]
NeuroVoices: Jiwon Oh, MD, PhD, on Radiologically Isolated Syndrome as a Precursor to MSMarch 9th 2022
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.
The Need for Guidelines on the Management of Radiologically Isolated Syndrome: Jiwon Oh, MD, PhDMarch 8th 2022
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.
MS Relapses, Health Care Utilization Greatest Among COVID-19 Vaccinated Patients Treated With Ocrelizumab, FingolimodMarch 7th 2022
Previously reported data show patients with multiple sclerosis treated with anti-CD20s have reduced response to COVID-19 vaccines, but there has been limited research on MS outcomes among vaccinated patients.
Differentiating Radiologically Isolated Syndrome and Multiple Sclerosis With Imaging Biomarkers: Jiwon Oh, MD, PhDMarch 7th 2022
The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed her presentation at ACTRIMS Forum 2022 involving imaging biomarkers of RIS/MS prodrome. [WATCH TIME: 4 minutes]
Understanding Frequency, Age, and Sex Associations With Autoimmune Encephalitis Biomarkers: Amy Kunchok, MDMarch 4th 2022
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research discussed the results of a new study on age and sex as determinants of autoimmune encephalitis. [WATCH TIME: 3 minutes]
Online Adaptive Cognitive Training, tDCS Feasible for Patients With Multiple SclerosisMarch 2nd 2022
Data suggest that there is a greater cognitive benefit for patients with higher levels of baseline neurological disability treated with the training and transcranial direct current stimulation.